Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

ABSTRACT: Glatiramer Acetate (GA) has provided safe and effective treatment for multiple sclerosis (MS) patients for two decades. It acts as an antigen, yet the precise mechanism of action remains to be fully elucidated, and no validated pharmacokinetic or pharmacodynamic biomarkers exist. In order to better characterize GA's biological impact, genome-wide expression studies were conducted with a human monocyte (THP-1) cell line. Consistent with previous literature, branded GA upregulated anti-inflammatory markers (e.g. IL10), and modulated multiple immune-related pathways. Despite some similarities, significant differences were observed between expression profiles induced by branded GA and Probioglat, a differently-manufactured glatiramoid purported to be a generic GA. Key results were verified usi

SUBMITTER: Kolitz S 

PROVIDER: S-EPMC4441120 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature